M&A Activity Will Accelerate In European Markets, Slow Down In U.S., Schering CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Rx drug industry can expect to see much more merger activity among European companies, while consolidation in the U.S. has essentially tapered off, Schering-Plough CEO Fred Hassan asserted May 19